Abstracts tagged "methotrexate (MTX)"

Abstract Number: 455 • 2012 ACR/ARHP Annual Meeting
Lack of Additive Benefits of Concomitant Methotrexate Use to Tocilizumab Monotherapy for Rheumatoid Arthritis in Daily Clinical Practice
Keisuke Izumi¹, Yuko Kaneko², Hidekata Yasuoka³, Noriyuki Seta⁴, Hideto Kameda⁵, Masataka Kuwana⁵ and Tsutomu Takeuchi⁶, ¹Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ²Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, Keio university, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Keio University School of Medicine, Tokyo, Japan
Background/Purpose: To explore the benefit of concomitant use of methotrexate (MTX) for the effectiveness of TCZ in rheumatoid arthritis (RA) patients in daily clinical practice.…
Abstract Number: 1849 • 2012 ACR/ARHP Annual Meeting
Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Bruno Fautrel¹, Benjamin Granger², Bernard Combe³, Francis Guillemin⁴, Alain Saraux⁵ and Xavier Le Loët⁶, ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁶Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Rapid radiographic progression (RRP) – i.e., increase of the Sharp/van der Heijde score (vSHS) ≥ 5 points during the 1st year – is a…
Abstract Number: 398 • 2012 ACR/ARHP Annual Meeting
Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission
Heather Jones¹, Annette Szumski² and Andrew S. Koenig³, ¹Pfizer Inc., Collegeville, PA, ²Specialty Care, Pfizer Inc., Collegeville, PA, ³Specialty Care Business Unit, Pfizer Inc., Collegeville, PA
Background/Purpose: The role of body mass index (BMI) in rheumatoid arthritis (RA) disease activity and response to treatment has been difficult to determine.1 As a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].